Treatment of Parkinson disease with diet-induced hyperketonemia: A feasibility study

  title={Treatment of Parkinson disease with diet-induced hyperketonemia: A feasibility study},
  author={Theodore B. Vanitallie and Cathy A. Nonas and Alessandro Di Rocco and Karyn L. Boyar and K Hyams and Steven B. Heymsfield},
  pages={728 - 730}
Ketones may bypass the defect in complex I activity implicated in Parkinson disease (PD). [] Key Result Five of seven volunteers with PD were able to prepare a "hyperketogenic" diet at home and adhere to it for 28 days. Substituting unsaturated for saturated fats appeared to prevent cholesterol increases in four volunteers. Unified Parkinson's Disease Rating Scale scores improved in all five during hyperketonemia, but a placebo effect was not ruled out.

Tables from this paper

The therapeutic potential of ketone bodies in Parkinson’s disease

A class of endogenous functional metabolites, ketone bodies, which have properties seemingly suited to rescuing mitochondrial function, have been largely overlooked and are being considered for use in clinical trials.

Nutritional Ketosis in Parkinson’s Disease — a Review of Remaining Questions and Insights

Research pertaining to ketogenic diet, exogenous ketones, fasting, clinical studies, and theoretical review papers regarding therapeutic mechanisms from direct ketone body signaling and indirect metabolic effects are reviewed to establish with greater certainty that there is a reliable symptomatic benefit.

The ketogenic diet: Uses in epilepsy and other neurologic illnesses

A growing body of literature suggests the ketogenic diet may be beneficial in certain neurodegenerative diseases, including Alzheimer disease, Parkinson’s disease, and amyotrophic lateral sclerosis, in which it appears to be neuroprotective.

Clinical Aspects of the Ketogenic Diet

This critical analysis of the ketogenic diet should provide the impetus for further clinical and basic research into the diet's application and mechanisms of action.

Nutritional aspects in Parkinson’s disease

The recent literature on the observed nutrition disorders and the possible role of diet and nutrients in the prevention and potential regression of PD, as well as dietary interventions and supplementation used to manage the disease is revised.

Diet and medical foods in Parkinson’s disease

Ketogenic Diet and Health

A brief review describes a selection of the recent studies of KD as applied to chronic metabolic diseases, and provides an estimate of the quality of the evidence for KD’s effects.

The Ketogenic Diet as a Treatment Paradigm for Diverse Neurological Disorders

The concept that many neurological conditions are linked pathophysiologically to energy dysregulation could well provide a common research and experimental therapeutics platform, from which the course of several neurological diseases could be favorably influenced by dietary means.

Ketogenic diet and fasting diet as Nutritional Approaches in Multiple Sclerosis (NAMS): protocol of a randomized controlled study

Whether a KD and a FD are superior to a standard diet (SD) in terms of therapeutic effects and disease progression is investigated in a single-center, randomized, controlled, parallel-group study of multiple sclerosis.

Diet and the Risk of Parkinson's Disease — Research Suggests Dietary Interventions May Prevent It and Lessen Symptom Severity

There’s no single cause of PD, but it has been suggested that the disease is caused by some combination of genetic predisposition and environmental factors, such as exposure to certain pesticides and heavy metals.



Ketones: metabolism's ugly duckling.

Because ketones are efficiently used by mitochondria for ATP generation and may also help protect vulnerable neurons from free radical damage, hyperketogenic diets should be evaluated for ability to benefit patients with PD, AD, and certain other neurodegenerative disorders.

The ketogenic diet: 1997.

The ketogenic diet offers a new paradigm to think about epilepsy and its treatment, and perhaps will stimulate new approaches to this still often devastating condition.

D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease.

It is shown that addition of 4 mM d-beta-hydroxybutyrate protected cultured mesencephalic neurons from MPP(+) toxicity and hippocampal neurons from Abeta(1-42) toxicity, suggesting that ketone bodies may play a therapeutic role in these most common forms of human neurodegeneration.

Ketone Bodies, Potential Therapeutic Uses

Surprisingly, D‐ β‐hydroxybutyrate (abbreviated “βOHB”) may also provide a more efficient source of energy for brain per unit oxygen, supported by the same phenomenon noted in the isolated working perfused rat heart and in sperm.

Plasma levels of amino acids correlate with motor fluctuations in parkinsonism.

Seven patients with Parkinson's disease who experienced severe motor fluctuations in response to levodopa were studied in detail with relation to the effect of dietary protein on their motor

Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children.

A high-fat ketogenic diet produced significant increases in the atherogenic apoB-containing lipoproteins and a decrease in the antiatherogenic HDL cholesterol.

Differential metabolic effects of saturated versus polyunsaturated fats in ketogenic diets.

It is demonstrated that a short-term POLY KD induces a greater level of ketosis and improves S(I), without adversely affecting total and low-density lipoprotein cholesterol, compared with a traditional SAT KD.

A ketogenic diet favorably affects serum biomarkers for cardiovascular disease in normal-weight men.

The results suggest that a short-term ketogenic diet does not have a deleterious effect on CVD risk profile and may improve the lipid disorders characteristic of atherogenic dyslipidemia.

Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease

The Unified Parkinson's Disease Rating Scale (UPDRS) is primarily composed of an investigator‐derived objective rating of motor function and a patient‐derived assessment of activities of daily living

Complex I and Parkinson's Disease

Chronic rotenone exposure accurately recapitulated the pathological, biochemical, and behavioral features of PD, suggesting relatively subtle complex I abnormalities‐‐either genetic or acquired‐‐may be central to the pathogenesis of PD.